Loading
Stephenson Cancer Center, OU Health
Oklahoma's only NCI-designated centre, consistently among the top enrollers in NRG gynaecologic trials and home of the SOLO1 and MIRASOL ovarian cancer lead investigator.
Overview
NCI-designated in 2018, Stephenson Cancer Center is the only NCI centre in Oklahoma and serves a state with large American Indian populations. Its gynaecologic oncology group is one of the most productive in the NCI's National Clinical Trials Network: Kathleen Moore led SOLO1, which established olaparib maintenance in newly diagnosed BRCA-mutated ovarian cancer, and MIRASOL, which confirmed the folate receptor alpha ADC mirvetuximab soravtansine in platinum-resistant disease. The Oklahoma Tobacco Research Center and TSET-funded cancer control programmes address the state's high smoking rates, and the centre runs an active phase 1 programme.
Location
Oklahoma City, OK, US
Type
cancer center · University of Oklahoma
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
clinical
OnCo score
#168 · 32 points (0 Newsweek + 8 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-15.
Matched to OU Health, including child institutions. 414 works · 5,765 citations · 63% open access · 21% clinical trials · 2% reviews.
Oncology works per year
792022
652023
782024
1262025
662026
Most works
- Abdul Rafeh Naqash89 works
- Kathleen N. Moore45 works
- Alessio Cortellini33 works
- Susanna Varkey Ulahannan32 works
- Michelle L. Churchman23 works
- Amin H. Nassar22 works
- Ryan David Nipp21 works
- David James Pinato21 works
- Ahmad A. Tarhini21 works
- Aik Choon Tan19 works
Most cited
Programmes
3- Gynaecologic oncology trials (NRG)
- Ovarian cancer (PARP inhibitors, FRα ADCs)
- Tobacco research
People
1Connected
13Similar pages
- TrialMIRASOL / GOG-3045
Shares Kathleen N. Moore, Folate receptor alpha, Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
- PersonUrsula A. Matulonis
Shares Folate receptor alpha, Mirvetuximab soravtansine, PARP, Olaparib.
- TrialSOLO-1
Shares Kathleen N. Moore, PARP inhibitors, PARP, Olaparib.
- CompanyGOG Foundation
Shares Kathleen N. Moore, Mirvetuximab soravtansine, NRG Oncology, National Cancer Institute (NIH).
- PersonJonathan A. Ledermann
Shares PARP inhibitors, PARP, Olaparib, Ovarian cancer.
- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
- PersonAmit M. Oza
Shares PARP, Olaparib, Endometrial cancer, Ovarian cancer.
cancers
technologies
targets
drugs
ApprovedADC
Mirvetuximab soravtansine · Elahere
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza
companies
institutions
people
bottlenecks
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ouhealth.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/